Reducing Risk from Bacterial Endospores in Aseptic Preparation Supported by Cherwell
Cherwell Laboratories have highlighted their ongoing support for the education and training of staff in aseptic production facilities — particularly given current focus on reducing risk from bacterial endospores in aseptic preparation. Summer 2015 will provide several opportunities for the discussion of new MHRA guidelines for Specials Manufacturers, regarding the development of best practice for the transfer disinfection process and potential alternatives.
Cherwell Laboratories will be attending two events spotlighting these new guidelines in July. On the 1 July Pharmig present Sporicides — As Part Of Your Transfer Process. This 1-day course will be run in Solihull in conjunction with the NHS and is aimed at staff that monitor, run or work in an aseptic facility. The annual 4-day CPD accredited course Aseptic Preparation and Dispensing of Medicines (APDM), starts on the 6 July. Organised jointly by the NHS, Technical Specialist Education and Training (TSET) and the University of Leeds, the course is designed to extend the knowledge of personnel working in licensed and unlicensed aseptic units.
At both of these events Cherwell Laboratories will be on hand with experts to discuss environmental monitoring, sporicidal disinfection, and process validation. Cherwell’s exhibition stand will present some of the tools and materials on offer including Redipor prepared media, SAS microbial air samplers, Mar Cor Dry Fog microbial decontamination and Mar Cor sporicidal disinfectants.
Andrew Barrow, Sales Manager, Cherwell Laboratories, who will be attending the events, commented: “Aseptic production in NHS pharmacies is critical to patient safety and a key focus area for Cherwell. The autumn conference season will almost certainly also feature discussion of this critical area and we at Cherwell Laboratories will continue to support and contribute wherever it is appropriate.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.